VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Amgen Inc. vs Pfizer Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Pfizer Inc.
PFE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); Pfizer Inc. has 5 segments (47.4% in Primary Care).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Amgen Inc. has 5 moat types across 3 domains; Pfizer Inc. has 8 across 3.
Primary market context
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
47.4%
Side-by-side metrics
Moat coverage
Shared moat types
Amgen Inc. strengths
Pfizer Inc. strengths
Segment mix
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Pfizer CentreOne
Competitive
Pfizer Ignite
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.